Sign in

    Bill Morgan • Canaccord Genuity

    Bill Morgan is a Managing Director and Senior Equity Analyst at Canaccord Genuity, specializing in coverage of innovative biopharmaceutical and life sciences companies. He regularly provides research and investment ratings for firms such as Celldex Therapeutics, issuing detailed reports and performance forecasts, with his coverage reflected in market-average buy ratings and consensus price targets. Morgan began his career in equity research in the early 2000s, holding analyst roles at other investment banks before joining Canaccord Genuity, where he has built a reputation for timely and actionable insights. He is a registered securities professional with FINRA and holds multiple investment industry credentials.

    Bill Morgan's questions to Fate Therapeutics Inc (FATE) leadership

    Bill Morgan's questions to Fate Therapeutics Inc (FATE) leadership • Q1 2024

    Question

    Bill Morgan of Canaccord Genuity asked how the company thinks about translating PK data from oncology patients to autoimmune patients, considering the key role of antigen-dependent expansion for CAR-T therapies.

    Answer

    CEO Scott Wolchko conceded that much is still unknown about the translation between the two disease settings. While they have observed CD19-mediated, dose-dependent expansion, he does not presume the PK profiles will be identical. He stressed that the most critical endpoint is the kinetics and depth of B-cell depletion, which is the therapy's primary mechanism of action.

    Ask Fintool Equity Research AI